DEF 14A: Biotricity Inc. Seeks Stockholder Approval for Director Elections, Accounting Firm Ratification, and Potential Equity Issuance

Biotricity Inc. is holding its annual meeting of stockholders on August 15, 2024, to vote on the election of directors, ratification of its accounting firm, approval of a potential equity issuance, and an adjournment proposal.

Summary

• Biotricity Inc. will hold its annual meeting of stockholders on August 15, 2024, to vote on several key proposals.
• Stockholders will elect four directors to serve until the next annual meeting.
• They will also vote to ratify the appointment of SRCO Professional Corporation as the company's independent registered public accounting firm for the year ending March 31, 2025.
• A significant proposal involves approving the issuance of up to $6.6 million of common stock upon conversion of Series B Convertible Preferred Stock, without regard to Nasdaq's 20% rule.
• Additionally, stockholders will vote on a proposal to allow the meeting to be adjourned if necessary to solicit additional proxies.
• The board of directors recommends voting FOR all proposals.

Sentiment

Score: 6

Explanation: The document is neutral in tone, primarily providing factual information about the upcoming annual meeting and proposals. The potential dilution is a concern, but the company is taking necessary steps to secure funding and comply with regulations.

Positives

• The board of directors is actively seeking stockholder input on key company decisions.
• The company is taking steps to ensure compliance with Nasdaq listing rules.
• The company has an audit committee that is responsible for selecting a qualified firm to serve as the independent registered public accounting firm to audit our financial statements.

Negatives

• The potential issuance of common stock could dilute existing stockholders' ownership.
• The conversion prices of the Series B Preferred Stock are based on the market price or offering price of our common stock (and may be below the Minimum Price), it is not possible to calculate the maximum number of shares of our common stock that may be issued upon conversion in full of the Series B Preferred Stock.
• The exact magnitude of the dilutive effect cannot be conclusively determined, but the dilutive effect may be material to our current stockholders.

Risks

• The market price of the company's common stock could decline due to the issuance and resale of shares.
• The increased number of issued shares could discourage the possibility of, or render more difficult, certain mergers, tender offers, proxy contests or other change of control or ownership transactions.
• The interests of the Purchasers may not be in the best interests of all stockholders.

Future Outlook

The company is seeking stockholder approval to proceed with the potential issuance of common stock upon conversion of the Series B Preferred Stock, which is intended to provide additional capital. The company is also focused on maintaining compliance with Nasdaq listing rules.

Management Comments

• The Board of Directors recommends that you vote FOR the proposals set forth in this Notice of Annual Meeting of Stockholders and the Proxy Statement.

Industry Context

The company operates in the medical device industry, which is subject to regulatory oversight and requires ongoing investment in research and development. The company's need for additional capital is common in this industry, particularly for early-stage companies.

Comparison to Industry Standards

• The need for shareholder approval for equity issuances exceeding 20% is a standard requirement under Nasdaq Listing Rule 5635(d), ensuring shareholder oversight of significant dilutive transactions.
• The terms of the Series B Convertible Preferred Stock, including the conversion price and dividend rate, are typical for private placements in the micro-cap sector, often involving downside protection for investors through adjustable conversion prices.
• The executive compensation structure, including base salaries and bonus potential, is generally aligned with industry standards for companies of similar size and stage, with equity-based incentives to align management interests with shareholder value creation.

Stakeholder Impact

• Stockholders may experience dilution of their ownership if the Series B Preferred Stock is converted.
• The outcome of the votes will determine the composition of the board of directors and the company's ability to raise capital.
• Employees are indirectly impacted by the company's financial stability and strategic direction.

Next Steps

• Stockholders need to review the proxy materials and vote on the proposals.
• The company will hold the annual meeting on August 15, 2024, to tabulate the votes.
• The company will file a Current Report on Form 8-K with the SEC to announce the final voting results.

Key Dates

Keywords

proxy statement, annual meeting, stockholders, directors, SRCO Professional Corporation, Series B Preferred Stock, common stock, equity issuance, Nasdaq, dilution, Biotricity